The global organ transplant immunosuppressant drugs market is fairly consolidated, with the top 5 vendors contributing over 90% of the market in 2014. Transparency Market Research (TMR) notes that these leading companies–Novartis AG, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi–are offering a robust and diverse product portfolio, including blockbuster drugs, to consolidate their market shares. They are updating their pipelines after the impending patient expiry of blockbuster drugs.
The increasing incidence rate of various life-threatening ailments has stimulated the demand for organ replacement therapies and transplants as the last line of treatment to treat organ failures or disabilities. This is a key driver fuelling the growth of the market. According to the TMR’s estimation, the global organ transplant immunosuppressant market was valued at US$5.1 bn in 2014. The market is anticipated to register a CAGR of -5.0% between 2015 and 2023 with the market’s valuation estimated to reach US$3.2 bn by 2023.
Immunosuppressant Drugs for Successful Kidney Transplantation Propel Market Growth
Over the last couple of years, kidney transplantation has emerged as the preferred treatment method for end-stage kidney disorder, as the replacement proves to be more cost-effective than dialysis. The use of immunosuppressant drugs has been considered as a vital element for the long-term success of kidney transplants. According to findings by TMR, the segment occupied over 53.4% of the market in 2014 and is expected to lead the market through 2023. Rising incidence rate of kidney disorders is expected to fuel the growth of this segment. Furthermore, the rising incidence other of chronic ailments, which may need liver, heart, and lung transplants, mainly among geriatric population, is expected to spur the demand for organ transplant immunosuppressant drugs.
In addition, the emerging demand for bone marrow transplant has expedited the discovery of novel immunosuppressant drugs and therapies. Recent developments suggest that immunosuppression is found to offer promising line of treatment for the management of graft-versus-host diseases.
High Cost of Organ Replacement Surgeries may Act as Restraint
The high cost of organ transplant procedures, significant shortage of donors, and the considerable expenditure required for the care of patients post-transplantation are likely to restrain the growth of the market in some regions. Combined with them, the non-adherence of the immunosuppression therapies after transplantation owing to the lack of awareness among patients is another key restraining factor. Additionally, uncertainty of benefits of the use of immunosuppression for complex transplantation procedures, especially evident in case of liver transplantation, has impeded the market growth. In addition, the advent of stem cell therapies as a potential substitute for organ transplantation may restrict the growth of the global organ transplant immunosuppressant drugs market.
However, extensive clinical studies and R&D activities undertaken to develop and test novel immunosuppressant therapeutics is a key trend that will help minimize the cases of organ rejection for a number of transplantations, unlocking promising growth opportunities for the market players.
Robust Healthcare Infrastructure to Spur Demand for Organ Transplant Immunosuppressant Drugs in North America
Regionally, North America is a prominent market for organ transplant immunosuppressant drugs. The growth is driven by the increasing rate of successful organ replacement surgeries and substantial investments from the government and private players to develop a robust healthcare infrastructure.
Europe is another region exhibiting tremendous potential for growth in the organ transplant immunosuppressant drugs market. Continuous advancements in surgical procedures for organ transplantation and innovations in immunosuppressant drug discovery are the crucial factors propelling the market growth in the region.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”
The global organ transplant immunosuppressant drugs market is segmented into:
- Calcineurin Inhibitors
- Antiproliferative Agents
- Mycophenolate Mofetil
- Mycophenolate Sodium
- mTOR Inhibitors
- Antithymocyte Globulin
- Bone Marrow
- Others (Intestinal and Multi-visceral Organs)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC